Sanofi (SNYNF)
SNYNF is quoted over the counter, not listed on an exchange. Sanofi files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Closes: Yahoo Finance daily closes, last bar 2026-11-13.
Profile
| Field | Value |
|---|---|
| Ticker | SNYNF, quoted over the counter |
| SEC CIK | 0001121404 |
| OTC Markets tier | Pink (price source, 2026-11-13) |
| SEC industry code | Pharmaceutical Preparations |
| Business address | Paris, France |
| Incorporated in | France |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-02-17 |
| Cash and burn | 7.7B EUR cash; operating cash flow 2.7B EUR a quarter. | Report 2025-12-31 |
| Shares outstanding | 2,438,854,192 (2025-12-31); 2,526,245,442 a year earlier; 2,521,671,464 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Forvis Mazars SA, Levallois-Perret, France | PCAOB Form AP 2026-03-18 |
| Late filings, 12 months | 2 NT notices | NT 11-K 2026-06-30 |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | Not filed | 7.8B EUR | 10.8B EUR | 7.7B EUR | 18.7B EUR | Needs four quarters | 20-F 2026-02-17 |
| FY 2024 2024-12-31 | Not filed | 5.6B EUR | 9.1B EUR | 7.4B EUR | 16.1B EUR | Needs four quarters | 20-F 2026-02-17 |
| FY 2023 2023-12-31 | Not filed | 5.4B EUR | 10.3B EUR | 8.7B EUR | 16.5B EUR | Needs four quarters | 20-F 2026-02-17 |
| FY 2022 2022-12-31 | Not filed | 8.4B EUR | 10.5B EUR | 12.7B EUR | 19.2B EUR | Needs four quarters | 20-F 2025-02-13 |
| FY 2021 2021-12-31 | Not filed | 6.2B EUR | 10.5B EUR | 10.1B EUR | 20.3B EUR | Needs four quarters | 20-F 2024-02-23 |
| FY 2020 2020-12-31 | Not filed | 12.3B EUR | 7.4B EUR | 13.9B EUR | 22.6B EUR | Needs four quarters | 20-F 2023-02-24 |
| FY 2019 2019-12-31 | Not filed | 2.8B EUR | 7.7B EUR | 9.4B EUR | 24.6B EUR | Needs four quarters | 20-F 2022-02-23 |
| FY 2018 2018-12-31 | Not filed | 4.3B EUR | 5.5B EUR | 6.9B EUR | 24.6B EUR | Needs four quarters | 20-F 2021-03-04 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in EUR.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-10-29 |
| Latest annual report | 20-F | 2026-02-17 |
| Latest quarterly / interim | 6-K | 2026-10-30 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier